Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Exploring patient and public involvement in motor neuron disease research.

Musson LS, McDermott CJ, Hobson EV.

Amyotroph Lateral Scler Frontotemporal Degener. 2019 Aug 2:1-10. doi: 10.1080/21678421.2019.1643373. [Epub ahead of print]

PMID:
31373235
2.

Clinical trials in amyotrophic lateral sclerosis.

McDermott CJ.

Curr Opin Neurol. 2019 Jul 22. doi: 10.1097/WCO.0000000000000731. [Epub ahead of print]

PMID:
31335338
3.

Tracheostomy in motor neurone disease.

Turner MR, Faull C, McDermott CJ, Nickol AH, Palmer J, Talbot K.

Pract Neurol. 2019 Jul 4. pii: practneurol-2018-002109. doi: 10.1136/practneurol-2018-002109. [Epub ahead of print] Review.

PMID:
31273080
4.

Use of coping strategies in MND/ALS: Association with demographic and disease-related characteristics.

Schlüter DK, Holland DP, Mills RJ, McDermott CJ, Williams TL, Young CA; TONiC study group.

Acta Neurol Scand. 2019 Aug;140(2):131-139. doi: 10.1111/ane.13113. Epub 2019 May 22.

PMID:
31058309
5.

Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials.

van den Berg LH, Sorenson E, Gronseth G, Macklin EA, Andrews J, Baloh RH, Benatar M, Berry JD, Chio A, Corcia P, Genge A, Gubitz AK, Lomen-Hoerth C, McDermott CJ, Pioro EP, Rosenfeld J, Silani V, Turner MR, Weber M, Brooks BR, Miller RG, Mitsumoto H; Airlie House ALS Clinical Trials Guidelines Group.

Neurology. 2019 Apr 2;92(14):e1610-e1623. doi: 10.1212/WNL.0000000000007242. Epub 2019 Mar 8.

6.

Mutations in the Glycosyltransferase Domain of GLT8D1 Are Associated with Familial Amyotrophic Lateral Sclerosis.

Cooper-Knock J, Moll T, Ramesh T, Castelli L, Beer A, Robins H, Fox I, Niedermoser I, Van Damme P, Moisse M, Robberecht W, Hardiman O, Panades MP, Assialioui A, Mora JS, Basak AN, Morrison KE, Shaw CE, Al-Chalabi A, Landers JE, Wyles M, Heath PR, Higginbottom A, Walsh T, Kazoka M, McDermott CJ, Hautbergue GM, Kirby J, Shaw PJ.

Cell Rep. 2019 Feb 26;26(9):2298-2306.e5. doi: 10.1016/j.celrep.2019.02.006.

7.

Physicians' attitudes toward end-of-life decisions in amyotrophic lateral sclerosis.

Thurn T, Borasio GD, Chiò A, Galvin M, McDermott CJ, Mora G, Sermeus W, Winkler AS, Anneser J.

Amyotroph Lateral Scler Frontotemporal Degener. 2019 Feb;20(1-2):74-81. doi: 10.1080/21678421.2018.1536154. Epub 2019 Feb 21.

PMID:
30789031
8.

Novel genotype-phenotype and MRI correlations in a large cohort of patients with SPG7 mutations.

Hewamadduma CA, Hoggard N, O'Malley R, Robinson MK, Beauchamp NJ, Segamogaite R, Martindale J, Rodgers T, Rao G, Sarrigiannis P, Shanmugarajah P, Zis P, Sharrack B, McDermott CJ, Shaw PJ, Hadjivassiliou M.

Neurol Genet. 2018 Oct 24;4(6):e279. doi: 10.1212/NXG.0000000000000279. eCollection 2018 Dec. Erratum in: Neurol Genet. 2018 Dec 03;4(6):e300.

9.

Communication change in ALS: engaging people living with ALS and their partners in future research.

Judge S, Bloch S, McDermott CJ.

Disabil Rehabil Assist Technol. 2019 Oct;14(7):675-681. doi: 10.1080/17483107.2018.1498924. Epub 2018 Oct 4.

PMID:
30284928
10.

Efficacy of the Head Up collar in facilitating functional head movements in patients with Amyotrophic Lateral Sclerosis.

Pancani S, Tindale W, Shaw PJ, Mazzà C, McDermott CJ.

Clin Biomech (Bristol, Avon). 2018 Aug;57:114-120. doi: 10.1016/j.clinbiomech.2018.06.016. Epub 2018 Jun 25.

11.

Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model.

Westeneng HJ, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, Martin S, McDermott CJ, Thompson AG, Pinto S, Kobeleva X, Rosenbohm A, Stubendorff B, Sommer H, Middelkoop BM, Dekker AM, van Vugt JJFA, van Rheenen W, Vajda A, Heverin M, Kazoka M, Hollinger H, Gromicho M, Körner S, Ringer TM, Rödiger A, Gunkel A, Shaw CE, Bredenoord AL, van Es MA, Corcia P, Couratier P, Weber M, Grosskreutz J, Ludolph AC, Petri S, de Carvalho M, Van Damme P, Talbot K, Turner MR, Shaw PJ, Al-Chalabi A, Chiò A, Hardiman O, Moons KGM, Veldink JH, van den Berg LH.

Lancet Neurol. 2018 May;17(5):423-433. doi: 10.1016/S1474-4422(18)30089-9. Epub 2018 Mar 26.

12.

Development and validation of Spasticity Index-Amyotrophic Lateral Sclerosis.

Milinis K, Tennant A, Mills RJ, Al-Chalabi A, Burke G, Dick DJ, Ealing J, Hanemann CO, Harrower T, McDermott CJ, Majeed T, Pinto A, Talbot K, Williams T, Young CA; TONiC study group.

Acta Neurol Scand. 2018 Jul;138(1):47-54. doi: 10.1111/ane.12910. Epub 2018 Feb 21.

PMID:
29468643
13.

The TiM system: developing a novel telehealth service to improve access to specialist care in motor neurone disease using user-centered design.

Hobson EV, Baird WO, Partridge R, Cooper CL, Mawson S, Quinn A, Shaw PJ, Walsh T, Wolstenholme D, Mcdermott CJ.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):351-361. doi: 10.1080/21678421.2018.1440408. Epub 2018 Feb 16.

14.

Longitudinal Diffusion-Weighted Whole-Body MRI Demonstrates Dynamic Changes in Muscle Integrity in Motor Neuron Disease.

Pierry IA, Alix J, Rao DG, Hoggard N, Bigley J, McDermott CJ, Wilkinson ID, Shaw PJ, Jenkins TM.

J Neuromuscul Dis. 2018;5(1):107. doi: 10.3233/JND-179002. No abstract available.

PMID:
29278900
15.

Targeted Genetic Screen in Amyotrophic Lateral Sclerosis Reveals Novel Genetic Variants with Synergistic Effect on Clinical Phenotype.

Cooper-Knock J, Robins H, Niedermoser I, Wyles M, Heath PR, Higginbottom A, Walsh T, Kazoka M; Project MinE ALS Sequencing Consortium, Ince PG, Hautbergue GM, McDermott CJ, Kirby J, Shaw PJ.

Front Mol Neurosci. 2017 Nov 9;10:370. doi: 10.3389/fnmol.2017.00370. eCollection 2017.

16.

Imaging muscle as a potential biomarker of denervation in motor neuron disease.

Jenkins TM, Alix JJP, David C, Pearson E, Rao DG, Hoggard N, O'Brien E, Baster K, Bradburn M, Bigley J, McDermott CJ, Wilkinson ID, Shaw PJ.

J Neurol Neurosurg Psychiatry. 2018 Mar;89(3):248-255. doi: 10.1136/jnnp-2017-316744. Epub 2017 Oct 31.

17.

Withdrawal of tracheostomy ventilation in motor neurone disease: implementing advance directives.

McDermott CJ, Faull C.

Pract Neurol. 2017 Oct;17(5):339-340. doi: 10.1136/practneurol-2017-001694. Epub 2017 Jul 17. No abstract available.

PMID:
28717052
18.

A comfort assessment of existing cervical orthoses.

Langley J, Pancani S, Kilner K, Reed H, Stanton A, Heron N, Judge S, McCarthy A, Baxter S, Mazzà C, McDermott CJ.

Ergonomics. 2018 Feb;61(2):329-338. doi: 10.1080/00140139.2017.1353137. Epub 2017 Jul 28.

19.

"Anything that makes life's journey better." Exploring the use of digital technology by people living with motor neurone disease.

Hobson EV, Fazal S, Shaw PJ, McDermott CJ.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 Aug;18(5-6):378-387. doi: 10.1080/21678421.2017.1288253. Epub 2017 Feb 20.

20.
21.

Management of oral secretions in neurological disease.

McGeachan AJ, Mcdermott CJ.

Pract Neurol. 2017 Apr;17(2):96-103. doi: 10.1136/practneurol-2016-001515. Epub 2017 Feb 10. Review.

22.

An Objective Functional Characterisation of Head Movement Impairment in Individuals with Neck Muscle Weakness Due to Amyotrophic Lateral Sclerosis.

Pancani S, Tindale W, Shaw PJ, McDermott CJ, Mazzà C.

PLoS One. 2017 Jan 9;12(1):e0169019. doi: 10.1371/journal.pone.0169019. eCollection 2017.

23.

A multicentre evaluation of oropharyngeal secretion management practices in amyotrophic lateral sclerosis.

McGeachan AJ, Hobson EV, Al-Chalabi A, Stephenson J, Chandran S, Crawley F, Dick D, Donaghy C, Ellis CM, Gorrie G, Hanemann CO, Harrower T, Jung A, Malaspina A, Morrison KE, Orrell RW, Talbot K, Turner MR, Williams TL, Young CA, Shaw PJ, McDermott CJ.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb;18(1-2):1-9. doi: 10.1080/21678421.2016.1221433. Epub 2016 Aug 31. Erratum in: Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb;18(1-2):152.

24.

Supportive and symptomatic management of amyotrophic lateral sclerosis.

Hobson EV, McDermott CJ.

Nat Rev Neurol. 2016 Sep;12(9):526-38. doi: 10.1038/nrneurol.2016.111. Epub 2016 Aug 12. Review.

25.

Is the last "man" standing in comedy the least funny? A retrospective cohort study of elite stand-up comedians versus other entertainers.

Stewart S, Wiley JF, McDermott CJ, Thompson DR.

Int J Cardiol. 2016 Oct 1;220:789-93. doi: 10.1016/j.ijcard.2016.06.284. Epub 2016 Jun 29.

PMID:
27394976
26.

DiPALS: Diaphragm Pacing in patients with Amyotrophic Lateral Sclerosis - a randomised controlled trial.

McDermott CJ, Bradburn MJ, Maguire C, Cooper CL, Baird WO, Baxter SK, Cohen J, Cantrill H, Dixon S, Ackroyd R, Baudouin S, Bentley A, Berrisford R, Bianchi S, Bourke SC, Darlison R, Ealing J, Elliott M, Fitzgerald P, Galloway S, Hamdalla H, Hanemann CO, Hughes P, Imam I, Karat D, Leek R, Maynard N, Orrell RW, Sarela A, Stradling J, Talbot K, Taylor L, Turner M, Simonds AK, Williams T, Wedzicha W, Young C, Shaw PJ.

Health Technol Assess. 2016 Jun;20(45):1-186. doi: 10.3310/hta20450.

27.

Diaphragm pacing in patients with amyotrophic lateral sclerosis - Authors' reply.

McDermott CJ, Bradburn MJ.

Lancet Neurol. 2016 May;15(6):543-4. doi: 10.1016/S1474-4422(16)30010-2. Epub 2016 Apr 11. No abstract available.

PMID:
27302116
28.

Enteral feeding in neurological disorders.

Stavroulakis T, McDermott CJ.

Pract Neurol. 2016 Oct;16(5):352-61. doi: 10.1136/practneurol-2016-001408. Epub 2016 May 5. Review.

29.

A mapping review of international guidance on the management and care of amyotrophic lateral sclerosis (ALS).

Janssens AI, Ruytings M, Al-Chalabi A, Chio A, Hardiman O, Mcdermott CJ, Meyer T, Mora G, Van Damme P, Van Den Berg LH, Vanhaecht K, Winkler AS, Sermeus W; ALS-CARE Consortium.

Amyotroph Lateral Scler Frontotemporal Degener. 2016 Jul-Aug;17(5-6):325-36. doi: 10.3109/21678421.2016.1167911. Epub 2016 Apr 14. Review.

PMID:
27078045
30.

Creatine kinase enzyme level correlates positively with serum creatinine and lean body mass, and is a prognostic factor for survival in amyotrophic lateral sclerosis.

Rafiq MK, Lee E, Bradburn M, McDermott CJ, Shaw PJ.

Eur J Neurol. 2016 Jun;23(6):1071-8. doi: 10.1111/ene.12995. Epub 2016 Mar 31.

PMID:
27029589
31.

Using technology to improve access to specialist care in amyotrophic lateral sclerosis: A systematic review.

Hobson EV, Baird WO, Cooper CL, Mawson S, Shaw PJ, Mcdermott CJ.

Amyotroph Lateral Scler Frontotemporal Degener. 2016 Jul-Aug;17(5-6):313-24. doi: 10.3109/21678421.2016.1165255. Epub 2016 Mar 30. Review.

32.

Establishing a pragmatic framework to optimise health outcomes in heart failure and multimorbidity (ARISE-HF): A multidisciplinary position statement.

Stewart S, Riegel B, Boyd C, Ahamed Y, Thompson DR, Burrell LM, Carrington MJ, Coats A, Granger BB, Hides J, Weintraub WS, Moser DK, Dickson VV, McDermott CJ, Keates AK, Rich MW.

Int J Cardiol. 2016 Jun 1;212:1-10. doi: 10.1016/j.ijcard.2016.03.001. Epub 2016 Mar 10. Review.

33.

Long-term physical activity: an exogenous risk factor for sporadic amyotrophic lateral sclerosis?

Harwood CA, Westgate K, Gunstone S, Brage S, Wareham NJ, McDermott CJ, Shaw PJ.

Amyotroph Lateral Scler Frontotemporal Degener. 2016 Jul-Aug;17(5-6):377-84. doi: 10.3109/21678421.2016.1154575. Epub 2016 Mar 21.

34.

Evaluating a novel cervical orthosis, the Sheffield Support Snood, in patients with amyotrophic lateral sclerosis/motor neuron disease with neck weakness.

Baxter S, Reed H, Clarke Z, Judge S, Heron N, Mccarthy A, Langley J, Stanton A, Wells O, Squire G, Quinn A, Strong M, Shaw PJ, Mcdermott CJ.

Amyotroph Lateral Scler Frontotemporal Degener. 2016 Jul-Aug;17(5-6):436-42. doi: 10.3109/21678421.2016.1148170. Epub 2016 Feb 26.

35.

The role of cranial and thoracic electromyography within diagnostic criteria for amyotrophic lateral sclerosis.

Jenkins TM, Alix JJ, Kandler RH, Shaw PJ, McDermott CJ.

Muscle Nerve. 2016 Sep;54(3):378-85. doi: 10.1002/mus.25062. Epub 2016 Jun 9.

36.

Assessment of the Sheffield Support Snood, an innovative cervical orthosis designed for people affected by neck muscle weakness.

Pancani S, Rowson J, Tindale W, Heron N, Langley J, McCarthy AD, Quinn A, Reed H, Stanton A, Shaw PJ, McDermott CJ, Mazzà C.

Clin Biomech (Bristol, Avon). 2016 Feb;32:201-6. doi: 10.1016/j.clinbiomech.2015.11.010. Epub 2015 Dec 2.

37.

Rueing the Roux-en-Y.

Lo C, Barker A, Kershaw H, Hickman SJ, McDermott CJ.

Pract Neurol. 2016 Jun;16(3):227-30. doi: 10.1136/practneurol-2015-001327. Epub 2015 Dec 9. No abstract available.

PMID:
26657498
38.

Gastrostomy in amyotrophic lateral sclerosis: effects of non-invasive ventilation - Authors' reply.

McDermott CJ, Stavroulakis T.

Lancet Neurol. 2015 Dec;14(12):1153. doi: 10.1016/S1474-4422(15)00294-X. No abstract available.

PMID:
26581966
39.

Head-Up; An interdisciplinary, participatory and co-design process informing the development of a novel head and neck support for people living with progressive neck muscle weakness.

Reed H, Langley J, Stanton A, Heron N, Clarke Z, Judge S, McCarthy A, Squire G, Quinn A, Wells O, Tindale W, Baxter S, Shaw PJ, McDermott CJ.

J Med Eng Technol. 2014;39(7):404-10. doi: 10.3109/03091902.2015.1088092.

PMID:
26453038
40.

Oligogenic inheritance of optineurin (OPTN) and C9ORF72 mutations in ALS highlights localisation of OPTN in the TDP-43-negative inclusions of C9ORF72-ALS.

Bury JJ, Highley JR, Cooper-Knock J, Goodall EF, Higginbottom A, McDermott CJ, Ince PG, Shaw PJ, Kirby J.

Neuropathology. 2016 Apr;36(2):125-34. doi: 10.1111/neup.12240. Epub 2015 Aug 24.

41.

Effect of lipid profile on prognosis in the patients with amyotrophic lateral sclerosis: Insights from the olesoxime clinical trial.

Rafiq MK, Lee E, Bradburn M, McDermott CJ, Shaw PJ.

Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7-8):478-84. doi: 10.3109/21678421.2015.1062517. Epub 2015 Jul 10.

PMID:
26161993
42.

A preliminary randomized trial of the mechanical insufflator-exsufflator versus breath-stacking technique in patients with amyotrophic lateral sclerosis.

Rafiq MK, Bradburn M, Proctor AR, Billings CG, Bianchi S, McDermott CJ, Shaw PJ.

Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7-8):448-55. doi: 10.3109/21678421.2015.1051992. Epub 2015 Jul 3.

PMID:
26140500
43.

Developing an outcome measure for excessive saliva management in MND and an evaluation of saliva burden in Sheffield.

McGeachan AJ, Hobson EV, Shaw PJ, McDermott CJ.

Amyotroph Lateral Scler Frontotemporal Degener. 2015 Mar;16(1-2):108-13. doi: 10.3109/21678421.2014.951942. Epub 2014 Sep 16.

PMID:
25225845
44.

The evidence for symptomatic treatments in amyotrophic lateral sclerosis.

Jenkins TM, Hollinger H, McDermott CJ.

Curr Opin Neurol. 2014 Oct;27(5):524-31. doi: 10.1097/WCO.0000000000000135. Review.

PMID:
25110934
45.

The impact of gastrostomy in motor neurone disease: challenges and benefits from a patient and carer perspective.

Stavroulakis T, Baird WO, Baxter SK, Walsh T, Shaw PJ, McDermott CJ.

BMJ Support Palliat Care. 2016 Mar;6(1):52-9. doi: 10.1136/bmjspcare-2013-000609. Epub 2014 May 21.

PMID:
24848262
46.

Loss of nuclear TDP-43 in amyotrophic lateral sclerosis (ALS) causes altered expression of splicing machinery and widespread dysregulation of RNA splicing in motor neurones.

Highley JR, Kirby J, Jansweijer JA, Webb PS, Hewamadduma CA, Heath PR, Higginbottom A, Raman R, Ferraiuolo L, Cooper-Knock J, McDermott CJ, Wharton SB, Shaw PJ, Ince PG.

Neuropathol Appl Neurobiol. 2014 Oct;40(6):670-85. doi: 10.1111/nan.12148.

PMID:
24750229
47.

Gene expression signatures in motor neurone disease fibroblasts reveal dysregulation of metabolism, hypoxia-response and RNA processing functions.

Raman R, Allen SP, Goodall EF, Kramer S, Ponger LL, Heath PR, Milo M, Hollinger HC, Walsh T, Highley JR, Olpin S, McDermott CJ, Shaw PJ, Kirby J.

Neuropathol Appl Neurobiol. 2015 Feb;41(2):201-26. doi: 10.1111/nan.12147.

48.

Factors influencing decision-making in relation to timing of gastrostomy insertion in patients with motor neurone disease.

Stavroulakis T, Baird WO, Baxter SK, Walsh T, Shaw PJ, McDermott CJ.

BMJ Support Palliat Care. 2014 Mar;4(1):57-63. doi: 10.1136/bmjspcare-2013-000497. Epub 2013 Dec 11.

PMID:
24644772
49.

TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions.

Gallagher MD, Suh E, Grossman M, Elman L, McCluskey L, Van Swieten JC, Al-Sarraj S, Neumann M, Gelpi E, Ghetti B, Rohrer JD, Halliday G, Van Broeckhoven C, Seilhean D, Shaw PJ, Frosch MP, Alafuzoff I, Antonell A, Bogdanovic N, Brooks W, Cairns NJ, Cooper-Knock J, Cotman C, Cras P, Cruts M, De Deyn PP, DeCarli C, Dobson-Stone C, Engelborghs S, Fox N, Galasko D, Gearing M, Gijselinck I, Grafman J, Hartikainen P, Hatanpaa KJ, Highley JR, Hodges J, Hulette C, Ince PG, Jin LW, Kirby J, Kofler J, Kril J, Kwok JB, Levey A, Lieberman A, Llado A, Martin JJ, Masliah E, McDermott CJ, McKee A, McLean C, Mead S, Miller CA, Miller J, Munoz DG, Murrell J, Paulson H, Piguet O, Rossor M, Sanchez-Valle R, Sano M, Schneider J, Silbert LC, Spina S, van der Zee J, Van Langenhove T, Warren J, Wharton SB, White CL 3rd, Woltjer RL, Trojanowski JQ, Lee VM, Van Deerlin V, Chen-Plotkin AS.

Acta Neuropathol. 2014 Mar;127(3):407-18. doi: 10.1007/s00401-013-1239-x. Epub 2014 Jan 19.

50.

The impact on the family carer of motor neurone disease and intervention with noninvasive ventilation.

Baxter SK, Baird WO, Thompson S, Bianchi SM, Walters SJ, Lee E, Ahmedzai SH, Proctor A, Shaw PJ, McDermott CJ.

J Palliat Med. 2013 Dec;16(12):1602-9. doi: 10.1089/jpm.2013.0211. Epub 2013 Nov 16.

Supplemental Content

Loading ...
Support Center